Back to top
more

BioLineRx (BLRX)

(Delayed Data from NSDQ)

$0.64 USD

0.64
339,418

+0.03 (4.64%)

Updated Apr 29, 2024 03:59 PM ET

After-Market: $0.64 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

1 item in cart

View Cart/Checkout

BioLineRx Ltd. [BLRX]

Reports for Purchase

Showing records 41 - 60 ( 202 total )

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 41

06/18/2018

Daily Note

Pages: 6

New Biomarker Directly Correlates With BL-8040 AML Induced Survival; Plethora of Upcoming Catalysts; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 42

05/22/2018

Company Report

Pages: 6

1Q18 Results; Prepping for Multiple Data Catalysts

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 43

03/06/2018

Company Report

Pages: 6

2017 Results; Investors Should Be Prepped Ahead of Several 2H18 Data Catalysts; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 44

01/17/2018

Daily Note

Pages: 6

Looks Like ''8040 Is Opening the Door; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 45

12/21/2017

Company Report

Pages: 6

The GENESIS of Company''s First Pivotal Program; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 46

12/06/2017

Company Report

Pages: 12

Brewing Excitement for 2018; Investor Day Recap; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 47

12/04/2017

Daily Note

Pages: 5

AML Needle Continues to Point in Right Direction; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 48

11/21/2017

Company Report

Pages: 5

3Q17 Results; Looking Toward a Busy Data Year in 2018; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 49

10/18/2017

Daily Note

Pages: 5

Genentech Collaboration Continues to Expand as Expected; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 50

09/26/2017

Company Report

Pages: 6

BL-8040 and Tecentriq Ready to BATTLE AML as Programs Expand

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 51

08/09/2017

Company Report

Pages: 6

2Q17 Results; The Password Is: BL-8040; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 52

08/09/2017

Company Report

Pages: 6

2Q17 Results; The Password Is: BL-8040; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 53

06/02/2017

Company Report

Pages: 5

Genentech Officially Presses Play; Meaningful Answers to Come; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 54

06/02/2017

Company Report

Pages: 5

Genentech Officially Presses Play; Meaningful Answers to Come; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 55

05/26/2017

Company Report

Pages: 5

1Q17 Results; All Eyes on ''8040 Collaborations and Pivotal Plans

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 56

05/26/2017

Company Report

Pages: 5

1Q17 Results; All Eyes on ''8040 Collaborations and Pivotal Plans

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 57

05/24/2017

Daily Note

Pages: 3

Corrected - Coverage Update - Healthcare

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 58

05/24/2017

Company Report

Pages: 4

We are transferring coverage due to the departure of the covering analyst. Shares will remain rated Under Review

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 59

05/24/2017

Daily Note

Pages: 3

Coverage Update - Healthcare

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 60

05/03/2017

Daily Note

Pages: 5

Stage Now Set to Go Pivotal; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party